Oxagen Limited Announces The Appointment Of David U'Prichard As Non-Executive Chairman 
10/19/2005 5:11:14 PM

Oxagen Limited, the drug discovery company focused on target identification and validation through human genetics, announces that Dr David U’Prichard is to join its board of directors at the end of May as Non-Executive Chairman. He replaces David White who will step down from the Oxagen board at that time. David U’Prichard brings significant and directly relevant R&D experience to the Company, in line with Oxagen’s strategic focus. Based in Philadephia, USA, Dr U’Prichard is President of Druid Consulting LLC, providing consulting services to the pharmaceutical and biotechnology industries and is a Venture Partner with Apax Partners Ltd. From 1999 to 2003 he was CEO of 3-Dimensional Pharmaceuticals Inc., which is now part of Johnson & Johnson. Previously he was Chairman of R&D at SmithKline Beecham and International Research Director for ICI/Zeneca.